TILRAY BRANDS INC (2HQ.DE) Stock Fundamental Analysis
Europe - FRA:2HQ - US88688T1007 - Common Stock
1.1495 EUR
-0.01 (-1.25%)
2HQ gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 53 industry peers in the Pharmaceuticals industry. 2HQ may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, 2HQ is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
2HQ had negative earnings in the past year.
In the past year 2HQ has reported a negative cash flow from operations.
In the past 5 years 2HQ always reported negative net income.
2HQ had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
2HQ has a Return On Assets of -105.42%. This is amonst the worse of the industry: 2HQ underperforms 88.68% of its industry peers.
2HQ has a worse Return On Equity (-144.68%) than 81.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.42% | ||
| ROE | -144.68% | ||
| ROIC | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
2HQ's Gross Margin of 29.29% is on the low side compared to the rest of the industry. 2HQ is outperformed by 77.36% of its industry peers.
In the last couple of years the Gross Margin of 2HQ has grown nicely.
The Profit Margin and Operating Margin are not available for 2HQ so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
2. Health
2.1 Basic Checks
2HQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 2HQ has more shares outstanding
2HQ has more shares outstanding than it did 5 years ago.
2HQ has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.22, we must say that 2HQ is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of 2HQ (-1.22) is worse than 75.47% of its industry peers.
2HQ has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.19, 2HQ is doing good in the industry, outperforming 77.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.22 |
ROIC/WACCN/A
WACC7.76%
2.3 Liquidity
2HQ has a Current Ratio of 2.46. This indicates that 2HQ is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.46, 2HQ is doing good in the industry, outperforming 79.25% of the companies in the same industry.
A Quick Ratio of 1.49 indicates that 2HQ should not have too much problems paying its short term obligations.
2HQ has a better Quick ratio (1.49) than 79.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.46 | ||
| Quick Ratio | 1.49 |
3. Growth
3.1 Past
2HQ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -648.00%.
2HQ shows a small growth in Revenue. In the last year, the Revenue has grown by 4.10%.
2HQ shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.52% yearly.
EPS 1Y (TTM)-648%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)4.1%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
3.2 Future
2HQ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.55% yearly.
The Revenue is expected to grow by 4.43% on average over the next years.
EPS Next Y97.18%
EPS Next 2Y40.87%
EPS Next 3Y26.96%
EPS Next 5Y15.55%
Revenue Next Year3.64%
Revenue Next 2Y4.1%
Revenue Next 3Y4.1%
Revenue Next 5Y4.43%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
2HQ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 2HQ. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
2HQ's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 2HQ is more expensive than 73.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 58.25 |
4.3 Compensation for Growth
A more expensive valuation may be justified as 2HQ's earnings are expected to grow with 26.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.87%
EPS Next 3Y26.96%
5. Dividend
5.1 Amount
2HQ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:2HQ (10/31/2025, 7:00:00 PM)
1.1495
-0.01 (-1.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners9.86%
Inst Owner ChangeN/A
Ins Owners0.36%
Ins Owner ChangeN/A
Market Cap1.29B
Revenue(TTM)821.31M
Net Income(TTM)-2186738000
Analysts72.5
Price Target1.66 (44.41%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2749.13%
Min EPS beat(2)-5362.97%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-1413.07%
Min EPS beat(4)-5362.97%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-730.51%
EPS beat(12)1
Avg EPS beat(12)-762.79%
EPS beat(16)3
Avg EPS beat(16)-613.4%
Revenue beat(2)0
Avg Revenue beat(2)-10.25%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-7.23%
Revenue beat(4)0
Avg Revenue beat(4)-8.93%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-4.66%
Revenue beat(8)0
Avg Revenue beat(8)-5.77%
Revenue beat(12)1
Avg Revenue beat(12)-3.93%
Revenue beat(16)1
Avg Revenue beat(16)-4.24%
PT rev (1m)83.53%
PT rev (3m)38.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.71%
EPS NY rev (1m)60.65%
EPS NY rev (3m)76.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.03%
Revenue NY rev (1m)0.58%
Revenue NY rev (3m)-1.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.82 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.99 | ||
| P/tB | 2.02 | ||
| EV/EBITDA | 58.25 |
EPS(TTM)-1.29
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.63
BVpS1.17
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.42% | ||
| ROE | -144.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.29% | ||
| FCFM | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
F-Score4
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 11.15 | ||
| Cap/Depr | 24.66% | ||
| Cap/Sales | 4.01% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.46 | ||
| Quick Ratio | 1.49 | ||
| Altman-Z | -1.22 |
F-Score4
WACC7.76%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.01%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-648%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y97.18%
EPS Next 2Y40.87%
EPS Next 3Y26.96%
EPS Next 5Y15.55%
Revenue 1Y (TTM)4.1%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
Revenue Next Year3.64%
Revenue Next 2Y4.1%
Revenue Next 3Y4.1%
Revenue Next 5Y4.43%
EBIT growth 1Y-11.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.7%
EBIT Next 3Y29.62%
EBIT Next 5Y17.51%
FCF growth 1Y-111.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-206.1%
OCF growth 3YN/A
OCF growth 5YN/A
TILRAY BRANDS INC / 2HQ.DE FAQ
What is the fundamental rating for 2HQ stock?
ChartMill assigns a fundamental rating of 2 / 10 to 2HQ.DE.
Can you provide the valuation status for TILRAY BRANDS INC?
ChartMill assigns a valuation rating of 1 / 10 to TILRAY BRANDS INC (2HQ.DE). This can be considered as Overvalued.
Can you provide the profitability details for TILRAY BRANDS INC?
TILRAY BRANDS INC (2HQ.DE) has a profitability rating of 1 / 10.
Can you provide the financial health for 2HQ stock?
The financial health rating of TILRAY BRANDS INC (2HQ.DE) is 3 / 10.